Evidence Hub

Successful management of Candida auris external ventricular shunt infection: a case report

A. El-Haj, D. Jawhar, Nawal Elfaki

Journal of Medical Case Reports, 2025

3 citations

Abstract

Candida auris ventriculitis is a rare but serious condition associated with high mortality rates. The available literature on its management is limited, and there are few documented successful treatment strategies or care plans. We report the case of a 34-year-old male patient from South Asia with Candida auris infection of an external ventricular shunt. The patient was initially treated with a combination of injectable amphotericin B liposomal and caspofungin for 21 days. This was followed by a 15-day course of injectable amphotericin liposomal and voriconazole. Subsequently, voriconazole monotherapy was administered orally for an additional 11 days. Notably, all antifungals used were determined to be sensitive on the basis of cerebrospinal fluid culture and sensitivity results. Source control was achieved after 20 days of initiating therapy, leading to the permanent removal of the shunt. Candida auris ventriculitis can be effectively managed with systemic antifungal therapy and appropriate source control measures.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free